All In Biotech

Drug Trial Radar · NCT05905484

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

A Phase 1, Double-blind, Single-dose, Randomized, Placebo and Active-Controlled, Four-Way Crossover Study Evaluating the Effects of Bemnifosbuvir on Cardiac Repolarization in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Apr 25, 2023

Primary completion

May 31, 2023

Study completion May 31, 2023

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects

Conditions

  • Healthy Volunteer Study

Interventions

  • Bemnifosbuvir (BEM)Drug

    A single dose of BEM will be administered.

  • PlaceboDrug

    A single dose of matching placebo will be administered.

  • MoxifloxacinDrug

    A single dose of Moxifloxacin will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-corrected (Δ) change-from-baseline QTc (ΔΔQTc).Time frame: 24 hours prior to dosing thru 48 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atea Study Site

    Québec, Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.